Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 9/20 | 0.36 |
| ▸ | JAK2 | O60674 | 8/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738226 | 1.00 | SYK (0.38) | SYKMETAXLPIK3CDJAK1 | |
| SCHEMBL26928603 | 0.89 | JAK1 (0.37) | SYKMETAXLJAK1JAK2 | |
| SCHEMBL30738144 | 0.83 | TNF (0.34) | SYKWNT3A | |
| SCHEMBL26928286 | 0.83 | TNF (0.34) | SYKWNT3A | |
| SCHEMBL26928641 | 0.82 | POLB (0.41) | METAXLPDE3BPDE3A | |
| SCHEMBL26928761 | 0.81 | CLK2 (0.36) | — | |
| SCHEMBL30738325 | 0.81 | CLK2 (0.36) | — | |
| SCHEMBL30738030 | 0.81 | GRM4 (0.33) | — | |
| SCHEMBL26955896 | 0.81 | GRM4 (0.33) | — | |
| SCHEMBL30738181 | 0.77 | ROCK2 (0.35) | METAXLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2023239729-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239729-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNA1, KCNB1, KCNB2 | SYK 3419/4885MET 4083/4885AXL 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.